Zealand Pharma Announces Financial Results for the Full Year 2023
In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.
- In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.
- In February 2024, Boehringer Ingelheim and Zealand Pharma announced positive results from the Phase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).
- In December 2023, Zealand submitted an NDA to the U.S. FDA for the treatment of adult patients with SBS dependent on parenteral support.
- A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/ .